Abstract: Objective: To observe the clinical effects of endoscopic hemostasis combined with intravenous drip of large dose Rabeprazole in the treatment of peptic ulcer bleeding high-risk patients. Methods: 83 cases of peptic ulcer bleeding high-risk patients were randomly divided into observation group and control group, and each group had 43 patients. The patients in observation group were treated with endoscopic hemostasis combined with intravenous drip of large dose Rabeprazole, while the patients in control group were treated with endoscopic hemostasis combined with intravenous drip of large dose Esomeprazole. The hemostatic treatment effect, hemostatic time, rehemorrhage rate and adverse effects of patients in 2 groups were compared. Results: There was no statistical significance of total effective rate, rehemorrhage rate at 72h and adverse effects rate between observation group and control group (P>0.05). The median hemostatic time of observation group was 25.5h, which was obviously shorter than control group (P<0.05). Conclusions: The therapeutic effects of treating peptic ulcer bleeding high-risk patients with endoscopic hemostasis combined intravenous drip of large dose Rabeprazole is equal to endoscopic hemostasis combined intravenous drip of large dose Esomeprazole; and combined intravenous drip of large dose Rabeprazole can obviously shorten hemostatic time, so it is worthy of clinical expansion.

Key words: Rabeprazole, Esomeprazole, Peptic ulcer bleeding

摘要： 目的: 观察内镜止血联合静脉滴注大剂量雷贝拉唑治疗消化性溃疡出血高危患者的临床疗效。方法: 消化性溃疡出血高危患者86例随机分为观察组和对照组,每组43例患者。观察组患者给予内镜止血联合大剂量雷贝拉唑治疗,对照组患者给予内镜止血联合大剂量艾司奥美拉唑治疗。比较两组患者的止血治疗效果、止血时间、再出血发生率和不良反应情况。结果: 两组患者治疗总有效率、72h后再出血发生率、不良反应发生率比较,差异无统计学意义（P>0.05）;观察组中位止血时间为25.5h,明显短于对照组（P<0.05）。结论: 内镜止血联合静脉滴注大剂量雷贝拉唑治疗消化性溃疡出血高危患者的疗效与内镜止血联合大剂量艾司奥美拉唑的治疗效果相当,且能明显缩短止血时间,值得临床推广。

关键词: 雷贝拉唑, 艾司奥美拉唑, 消化性溃疡出血